<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (GS) is a benign, familial condition characterized by recurrent asymptomatic non-hemolytic low-grade indirect hyper-<z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">bilirubinemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Conditions related to fasting, stress or co-morbidity might reveal the disease in asymptomatic individuals </plain></SENT>
<SENT sid="2" pm="."><plain>Seven patients who were treated for a <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> were identified with reversible indirect hyper-<z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">bilirubinemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Liver function tests in <z:hpo ids='HP_0000001'>all</z:hpo> of them, including <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels were <z:mpath ids='MPATH_458'>normal</z:mpath> before the therapeutic maneuver, which was the delivery of combined chemotherapy in three cases and a bone marrow transplantation in four (three allografts and one autograft) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi> levels returned to <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> five patients following treatment </plain></SENT>
<SENT sid="5" pm="."><plain>GS should not be overlooked in individuals exposed to these treatments who develop <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> and <z:hpo ids='HP_0000952'>jaundice</z:hpo> </plain></SENT>
</text></document>